Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 8 results
Author Title Type [ Year(Asc)]
Filters: Author is Klasse, P J  [Clear All Filters]
2020
Moore JP, Klasse PJ.  2020.  COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.. J Virol. 94(17)
2019
Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ et al..  2019.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.. J Virol. 93(4)
2018
Ozorowski G, Cupo A, Golabek M, LoPiccolo M, Ketas TA, Cavallary M, Cottrell CA, Klasse PJ, Ward AB, Moore JP.  2018.  Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers .. J Virol. 92(13)
Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC et al..  2018.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.. PLoS Pathog. 14(2):e1006913.
2015
Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW et al..  2015.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.. J Virol. 89(23):12189-210.
2011
Tsibris AMN, Pal U, Schure AL, Veazey RS, Kunstman KJ, Henrich TJ, Klasse PJ, Wolinsky SM, Kuritzkes DR, Moore JP.  2011.  SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses.. PLoS One. 6(12):e28047.
2010
Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP.  2010.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.. AIDS Res Hum Retroviruses. 26(4):445-58.
Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP.  2010.  Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.. J Infect Dis. 202(5):739-44.